Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,123 stopped studies mapped to Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,123 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06064279 | Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced…(HAITEN-ICI) | Phase 1 / Phase 2 | withdrawn | Oct 3, 2023 | VA Office of Research and Development | The funding for this trial was removed. | Funding |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | Phase 2 | withdrawn | Jun 29, 2021 | University of British Columbia | Overestimated pool of eligible patients and the potential participants either declined… | Other (stated, no rule matched) |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy… | Phase 2 | terminated | Jan 27, 2011 | Merck Sharp & Dohme LLC | Persistent low enrollment made study continuation no longer feasible | Enrollment / accrual |
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Phase 1 | terminated | Sep 18, 2018 | Pfizer | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology… | Safety / toxicity |
| NCT04348292 | Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer | Phase 1 | terminated | Apr 16, 2020 | Emory University | Accrual goal not met. | Enrollment / accrual |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT05849246 | The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab… | Phase 2 | terminated | May 8, 2023 | Innovent Biologics (Suzhou) Co. Ltd. | strategy terminates development, the decision is not due to any safety-related issues | Safety / toxicity |
| NCT03050554 | SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell… | Phase 1 / Phase 2 | terminated | Feb 13, 2017 | Andrew Sharabi | Funding | Funding |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | — | terminated | Jun 14, 2016 | Maastricht University Medical Center | Not feasible to include the needed patients | Other (stated, no rule matched) |
| NCT00998166 | A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy | Phase 2 | terminated | Oct 20, 2009 | Columbia University | Poor enrollment | Enrollment / accrual |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT04957602 | Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC…(LUTON) | — | terminated | Jul 12, 2021 | Hospices Civils de Lyon | funding ending | Funding |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient… | Phase 1 / Phase 2 | terminated | Dec 13, 2019 | Haihe Biopharma Co., Ltd. | Sponsor business decision | Sponsor / business decision |
| NCT05583188 | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage…(VIGOR) | Phase 4 | terminated | Oct 17, 2022 | Galvanize Therapeutics, Inc. | Strategic | Sponsor / business decision |
| NCT06507891 | A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334… | Phase 1 / Phase 2 | terminated | Jul 18, 2024 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | After considering the company's project situation and strategic development direction, it has been… | Safety / toxicity |
| NCT05364645 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | Phase 2 | withdrawn | May 6, 2022 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT02954523 | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR… | Phase 1 / Phase 2 | terminated | Nov 3, 2016 | Chul Kim | Lack of accrual | Enrollment / accrual |
| NCT04822298 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Phase 1 | terminated | Mar 30, 2021 | Amgen | Amgen made a business decision to discontinue AMG 160 20180273 | Sponsor / business decision |
| NCT02949843 | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With… | Phase 2 | terminated | Oct 31, 2016 | Wake Forest University Health Sciences | Slow accrual, closed by IRB | Enrollment / accrual |
| NCT04908956 | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous…(STEREO) | Phase 2 | terminated | Jun 1, 2021 | ETOP IBCSG Partners Foundation | The trial struggled with low activation due to the COVID pandemic. The Steering Committee took the… | COVID-19 / pandemic |
| NCT06093503 | Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care… | Phase 3 | withdrawn | Oct 23, 2023 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04402008 | Study of Poziotinib in Japanese Patients With NSCLC | Phase 1 / Phase 2 | terminated | May 26, 2020 | Spectrum Pharmaceuticals, Inc | Business decision, not related to safety. | Safety / toxicity |
| NCT05621525 | Phase I Study of the BBP-398 in Patients With Advance Solid Tumors | Phase 1 | terminated | Nov 18, 2022 | LianBio LLC | Business reason | Sponsor / business decision |
| NCT02840227 | The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients… | N/A | withdrawn | Jul 21, 2016 | The Cleveland Clinic | not stated | Not stated |
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy…(CANOPY-N) | Phase 2 | terminated | May 30, 2019 | Novartis Pharmaceuticals | Study early terminated due to low enrollment compared to the anticipated figures. | Enrollment / accrual |
| NCT05567055 | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA… | Phase 2 | withdrawn | Oct 5, 2022 | Timothy Burns, MD, PHD | Slow enrollment | Enrollment / accrual |
| NCT04037462 | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | Phase 1 / Phase 2 | terminated | Jul 30, 2019 | VA Office of Research and Development | Low accrual | Enrollment / accrual |
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer… | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | University of Texas Southwestern Medical Center | Funding Sponsor no longer supporting study | Funding |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT02974426 | To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2)… | Phase 3 | terminated | Nov 28, 2016 | Shanghai Chest Hospital | Enrollment was delayed and the number of eligible patients significantly declined with the use of… | Enrollment / accrual |
| NCT05435846 | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer… | Phase 1 | terminated | Jun 28, 2022 | Collin Blakely | slow accrual | Enrollment / accrual |
| NCT02309892 | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | Phase 1 | terminated | Dec 5, 2014 | Helix BioPharma Corporation | Slow enrolment - standard of care evolved over the duration of the study such that treatment… | Enrollment / accrual |
| NCT06288646 | Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of… | — | terminated | Mar 1, 2024 | Breathe BioMedical Inc | Change in sponsor's business strategy (disease focus changed to breast cancer) | Sponsor / business decision |
| NCT02635061 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Dec 18, 2015 | Celgene | Lack of efficacy | Efficacy / futility |
| NCT05493501 | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With… | Phase 3 | terminated | Aug 9, 2022 | EQRx International, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT04476797 | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC(GRECO-1) | Phase 1 / Phase 2 | terminated | Jul 20, 2020 | Galera Therapeutics, Inc. | Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to… | Efficacy / futility |
| NCT04211922 | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously… | Phase 2 | terminated | Dec 26, 2019 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Sponsor R\&D Strategy Adjustment | Sponsor / business decision |
| NCT06331585 | Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of… | Phase 2 | withdrawn | Mar 26, 2024 | Hetian District People's Hospital | work commitments | Other (stated, no rule matched) |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | Phase 1 / Phase 2 | terminated | Feb 2, 2023 | iOx Therapeutics | Prioritization of other pipeline assets. No safety or efficacy issues were observed. | Safety / toxicity |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab… | Phase 2 | terminated | Nov 4, 2016 | Mirati Therapeutics Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | Phase 2 | terminated | Feb 26, 2021 | GlaxoSmithKline | The study was terminated for reasons pertaining to feasibility | Other (stated, no rule matched) |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing… | Phase 2 | terminated | Jul 22, 2019 | National Cancer Institute (NCI) | Study was terminated due to slow accrual. | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | N/A | withdrawn | Jun 9, 2022 | Ohio State University Comprehensive Cancer Center | Funding lapse | Funding |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Phase 2 | terminated | Sep 30, 2016 | Dana-Farber Cancer Institute | Funding was pulled | Funding |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or… | Phase 2 | terminated | Mar 21, 2018 | Pfizer | The study was terminated since there was no need for further safety or efficacy data to be… | Safety / toxicity |
| NCT03866980 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung… | Phase 3 | terminated | Mar 7, 2019 | Akeso | corporate strategy adjustment | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials